Skip to main content

Guadecitabine and Durvalumab in Treating Patients with Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Trial Status: Closed to Accrual

This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread to other places in the body. Guadecitabine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with durvalumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving guadecitabine and durvalumab may work better in treating patients with liver, pancreatic, bile duct, or gallbladder cancer.

Inclusion Criteria

  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3) except for patients with HCC for whom ANC >= 1000 per mm^3 is allowed
  • Platelet count >= 100 x 10^9/L (>= 100,000 per mm^3), except for patients with HCC for whom a platelet count >= 60,000 per mm^3 is allowed
  • Hemoglobin >= 8.0 g/dL; if patients have a hemoglobin level below 8, blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at >= 8.0 g/dL for 7 days or longer without additional transfusion
  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal unless liver metastases are present or unless patient is known to have chronic liver disease (hepatitis) in which case AST and ALT must be =< 5 x institutional upper limit of normal (IULN)
  • Serum bilirubin =< 2.5 x institutional upper limit of normal (ULN)
  • Serum albumin >= 2.5 g/dL
  • Serum creatinine clearance (CL) > 40 mL/min by the Cockcroft-Gault formula or by 24-hour urine collection for determination of creatinine clearance
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: ** Has not undergone a hysterectomy or bilateral oophorectomy; or ** Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months) * Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: >= 60 years old and no menses for >= 1 year without an alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry
  • Ability to understand a written informed consent
  • Signed written informed consent and Health Insurance Portability and Accountability Act (HIPAA) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
  • Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
  • Patients must have measurable disease as defined by RECIST 1.1 criteria
  • Patients must have accessible lesions for pre-treatment and on treatment biopsies and must agree to the mandatory pre-treatment and on treatment (cycle 3 day 1) biopsies; exceptions may be granted only for the dose escalation patients after discussion with principal investigator (PI); biopsy at time of response or progression is optional
  • Hepatocellular carcinoma cohort specific criteria: * Patients must have a histologically proven diagnosis of hepatocellular carcinoma that is not amenable to curative surgical therapeutic options; please note that a radiologic diagnosis of HCC based on standard radiologic criteria as defined by American Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL) is acceptable to initiate screening and the histologic diagnosis can be confirmed as part of the pre-treatment biopsy on study * Patients must not be good candidates for locoregional therapy as determined by the investigator (ie diffuse multifocal disease, vascular involvement, etc) * Patients must have had evidence of radiologic progression on sorafenib or lenvatinib or have had intolerance to sorafenib or lenvatinib as defined by the recurrence of clinically significant toxicities despite a minimum of one dose reduction and appropriate supportive care; patients who refuse sorafenib or lenvatinib are eligible with documentation of refusal by the treating physician * Patients may have received other treatment for HCC such as embolization, chemoembolization, intra-arterial chemotherapy, ethanol injection, ablative therapy, cryosurgery, or other locoregional or targeted therapy * Patients must have a Child Pugh score of 7 points or less * International normalized ratio (INR) =< 2.3 or prothrombin time =< 6 seconds above control * Patients with hepatitis B infection must be on appropriate anti-viral therapy
  • Cholangiocarcinoma cohort specific criteria: * Patients must have histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease; patients with ampullary carcinoma are not eligible * Patients must have failed at least one (but no more than 3) prior line of systemic therapy in the advanced disease setting * Patients who received adjuvant chemotherapy and had evidence of disease recurrence within 6 months of completion of the adjuvant treatment are also eligible; in this case, the adjuvant therapy will count as the minimum required one prior line of therapy; if patient received adjuvant treatment and had disease recurrence after 6 months, patients will only be eligible after failing one regimen of systemic chemotherapy used to treat the (unresectable or metastatic) disease recurrence * If the patient has had decompression of the biliary tree within the last 14 days, stability of the bilirubin level needs to be confirmed with two measurements that are within 5 to 7 days of each other; (the second measurement must be obtained within 7 days prior to registration); both the first and second measurement must be =< 2.5 x IULN; stability is defined as the second measurement being no more than one point higher than the first
  • Pancreatic cancer cohort specific criteria: * Patients must have unresectable or metastatic pancreatic cancer * Patients must have failed at least one prior line of therapy for metastatic or unresectable disease or have recurred within 6 months of completing adjuvant chemotherapy * Patients with liver metastases must have < 50% involvement of the liver

Exclusion Criteria

  • Patients may not be receiving any other investigational agents
  • Patients must not be nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants
  • Patients may not have received any previous treatment with a hypomethylating agent, or with a PD1 or PD-L1 or anti-PD-L2 or anti-CTLA4 inhibitor, including durvalumab; any immunomodulatory agent that is not described above should be cleared by the PI
  • History of another primary malignancy except for: * Malignancy treated with curative intent and with no known active disease >= 3 years before the first dose of study drug * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease * Adequately treated carcinoma in situ without evidence of disease eg, cervical cancer in situ * Controlled, superficial bladder carcinoma * T1a or T1b or T1c prostate carcinoma treated with radiation >= 1 year prior to study enrollment and prostate specific antigen (PSA) within normal limits (WNL) since treatment * T2a or b prostate carcinoma treated curatively >= 1 year prior to study enrollment and PSA undetectable since curative treatment * Other scenarios of early stage prostate cancer therapy > 1 year prior to study enrollment, and with an acceptable PSA for the patient age should be discussed with the PI * Other concurrent early stage cancers that have a minimal chance of recurrence or progression while on study (i.e stage I endometrial cancer, cervical cancer, early stage thyroid papillary cancer, etc.) may be cleared by the PI
  • Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within 28 days prior to the first dose of study drug and within 6 weeks for nitrosourea or mitomycin C
  • Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from 3 electrocardiograms (ECGs) using Fridericia’s correction
  • Current or prior use of immunosuppressive medication within 28 days before the first dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid; live attenuated vaccines within 30 days of durvalumab dosing (ie, 30 days prior to the first dose, during treatment with durvalumab and for 30 days post discontinuation of durvalumab); inactivated vaccines, such as the injectable influenza vaccine, are permitted
  • Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or more from previous anti-cancer therapy, except alopecia, hearing loss, peripheral neuropathy or non-clinically significant laboratory abnormalities
  • Any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent (except clinically manageable dermatologic and endocrine irAE’s), or any unresolved irAE > grade 1
  • Active or prior documented autoimmune disease; subjects with vitiligo, Grave’s disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
  • Active or prior documented inflammatory bowel disease (e.g., Crohn’s disease, ulcerative colitis)
  • History of primary immunodeficiency
  • History of allogeneic organ transplant
  • History of hypersensitivity to durvalumab, guadecitabine (SGI-110) or any excipient
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active bacterial or viral infection (except hepatitis B or C), symptomatic congestive heart failure, uncontrolled hypertension (defined as systolic blood pressure [SBP] > 160 or diastolic blood pressure [DBP] > 100 on 2 separate occasions separated by at least 24 hours), unstable angina pectoris, clinically significant cardiac arrhythmia (except for rate controlled atrial fibrillation), active peptic ulcer disease or gastritis, active bleeding diathesis including any subject known to have evidence of human immunodeficiency virus (HIV), or psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
  • Known history of previous clinical diagnosis of tuberculosis
  • History of leptomeningeal carcinomatosis or uncontrolled seizures
  • Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving durvalumab
  • Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
  • Symptomatic or uncontrolled brain metastases requiring concurrent treatment, inclusive of but not limited to surgery, radiation and/or corticosteroids
  • Presence of non-malignant ascites that is not medically controlled or that required a therapeutic paracentesis within the last 3 months prior to initiation of study therapy; malignant ascites is allowed if cytologically confirmed and if patient is not requiring more than one paracentesis per month
  • Known history or ongoing diagnosis of pneumonitis
  • Hepatocellular carcinoma cohort specific exclusion criteria: * A history of hepatic encephalopathy within the past 12 months; patients on stable doses of lactulose for prophylaxis or as a result of previous hepatic encephalopathy (more than 12 months ago) are allowed (for HCC cohort only) * A history of bleeding esophageal or gastric varices within the last 6 months prior to initiation of study therapy


Los Angeles
Los Angeles County-USC Medical Center
Contact: Jessica Levano
Phone: 323-865-0593
USC / Norris Comprehensive Cancer Center
Contact: Anthony El-Khoueiry
Phone: 323-865-3967
Newport Beach
Hoag Memorial Hospital
Contact: Cristina de Leon
Phone: 949-764-5543


Johns Hopkins University / Sidney Kimmel Cancer Center
Contact: Nilofer Saba Azad
Phone: 410-955-8893


I. To evaluate the dose limiting toxicities and determine the maximum tolerated dose/recommended phase 2 dose of the combination of guadecitabine and durvalumab. (Dose escalation part)

II. To evaluate the objective response rate (per Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) for the combination of guadecitabine and durvalumab in hepatocellular carcinoma, pancreatic cancer and cholangiocarcinoma cohorts, respectively. (Expansion part)


I. To describe the safety and tolerability of the combination of guadecitabine and durvalumab.

II. To estimate the progression-free and overall survival of patients with advanced hepatocellular carcinoma (HCC), pancreatic cancer and biliary cancers treated with the combination of guadecitabine and durvalumab.


I. Correlate PD-L1 and PD1 expression on various cells within tumor samples and anti-tumor effect (response rate and survival).

II. Correlate effector T cells (Teff)/regulatory T cells (Treg) ratio in the tumor and anti-tumor effect.

III. Correlate granulocytic and monocytic myeloid-derived suppressor cells (MDSCs) level in the peripheral blood using fluorescence-activated cell sorting (FACS) and anti-tumor effect.

IV. Evaluate changes in inflammatory T cell signatures pre and post treatment and potential associations with anti-tumor effect.

V. Assess the induction, activation, expansion and tumor infiltration of tumor neo-epitope-specific T cells.

VI. Explore changes in gene methylation and expression with anti-tumor effect, with particular emphasis on the ancestry-informative marker (AIM) gene panel.

VII. Correlate immunologic changes in pre- and post-treatment peripheral blood mononuclear cell (PBMCs) and anti-tumor effect.

OUTLINE: This is a dose-escalation study of guadecitabine.

Patients receive guadecitabine subcutaneously (SC) once daily (QD) on days 1-5 and durvalumab intravenously (IV) over 60 minutes on day 8. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and then every 3 months thereafter.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
USC / Norris Comprehensive Cancer Center

Principal Investigator
Anthony El-Khoueiry

  • Primary ID 0S-16-18
  • Secondary IDs NCI-2017-01432
  • ID NCT03257761